Henry Schein (NASDAQ:HSIC) Posts Earnings Results

Henry Schein (NASDAQ:HSIC) posted its quarterly earnings data on Monday. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.11 by $0.04, RTT News reports. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.24 billion. During the same period in the previous year, the firm posted $1.10 earnings per share. The business’s revenue for the quarter was down .1% compared to the same quarter last year. Henry Schein updated its FY 2025 guidance to 4.800-4.940 EPS.

Henry Schein Stock Performance

NASDAQ HSIC opened at $66.58 on Tuesday. The stock has a market capitalization of $8.16 billion, a price-to-earnings ratio of 27.40, a PEG ratio of 2.13 and a beta of 0.87. The stock has a 50-day moving average of $67.89 and a 200 day moving average of $71.55. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. Henry Schein has a twelve month low of $60.56 and a twelve month high of $82.49.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the transaction, the chief executive officer now directly owns 62,688 shares of the company’s stock, valued at $4,460,251.20. This trade represents a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Philip A. Laskawy sold 2,604 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now owns 24,805 shares in the company, valued at approximately $1,762,147.20. This trade represents a 9.50 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

HSIC has been the subject of a number of research reports. StockNews.com cut Henry Schein from a “buy” rating to a “hold” rating in a research report on Thursday, April 17th. Barrington Research reduced their price target on shares of Henry Schein from $90.00 to $86.00 and set an “outperform” rating for the company in a research report on Tuesday. UBS Group dropped their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their target price for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Finally, Jefferies Financial Group upped their price target on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Henry Schein currently has an average rating of “Moderate Buy” and a consensus target price of $79.80.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.